Enclosed herewith is the Press Release with respect to the Performance of Unity Small Finance Bank Limited, a Material Subsidiary of the Company for the Quarter and Financial Year ended March 31, 2024 ...

GULSHAN POLYOLS LTD. - Disclosure Under Regulation 30 And Part A Of Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. The Company has been granted "Consent ...

The Exchange has sought clarification from Peninsula Land Ltd on May 6, 2024, with reference to Movement in Volume. <BR><BR>The reply is awaited.

Board of director of Ujaas Energy Limited in its meeting held on May 03, 2024 has approved May 17, 2024 as the record date for the purpose of implementing demerger of the business of Ujaas Energy ...

We are submitting herewith our reply to BSE''s email dated May 3, 2024 seeking clarification on price movement of the Company''s shares.

The Exchange has received the disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aevas Business Solutions Pvt Ltd ...

Intimation under Reg 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the purpose of allotment of equity ...

Waaree Renewable Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 ,inter alia, to consider and approve In continuation of our ...

In compliance with Reg 39(3) of SEBI (LODR) Regulations, 2015 and as informed by the RTA, intimation is hereby given regarding loss of shares certificates.

Mukka Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 ,inter alia, to consider and approve We wish to inform you that a meeting of the ...

PENINSULA LAND LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2024 ,inter alia, to consider and approve Board Meeting Pursuant To Regulation 29(1) ...

One of our subsidiary has received order from Assistant Director / Drug Controller. The detailed disclosure is enclosed.